- Home
- XBP vs MRSN Comparison
XBP vs MRSN Comparison
Compare XBP & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBP
- MRSN
- Stock Information
- Founded
- XBP 2020
- MRSN 2001
- Country
- XBP United States
- MRSN United States
- Employees
- XBP N/A
- MRSN N/A
- Industry
- XBP Business Services
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- XBP Consumer Discretionary
- MRSN Health Care
- Exchange
- XBP Nasdaq
- MRSN Nasdaq
- Market Cap
- XBP 32.2M
- MRSN 37.0M
- IPO Year
- XBP N/A
- MRSN 2017
- Fundamental
- Price
- XBP $0.61
- MRSN $7.75
- Analyst Decision
- XBP
- MRSN Strong Buy
- Analyst Count
- XBP 0
- MRSN 4
- Target Price
- XBP N/A
- MRSN $63.67
- AVG Volume (30 Days)
- XBP 9.1M
- MRSN 123.1K
- Earning Date
- XBP 08-14-2025
- MRSN 08-13-2025
- Dividend Yield
- XBP N/A
- MRSN N/A
- EPS Growth
- XBP N/A
- MRSN N/A
- EPS
- XBP N/A
- MRSN N/A
- Revenue
- XBP $148,332,000.00
- MRSN $34,769,000.00
- Revenue This Year
- XBP N/A
- MRSN N/A
- Revenue Next Year
- XBP N/A
- MRSN $1.03
- P/E Ratio
- XBP N/A
- MRSN N/A
- Revenue Growth
- XBP 0.23
- MRSN 16.14
- 52 Week Low
- XBP $0.42
- MRSN $5.21
- 52 Week High
- XBP $2.56
- MRSN $70.75
- Technical
- Relative Strength Index (RSI)
- XBP 43.52
- MRSN 53.41
- Support Level
- XBP $0.54
- MRSN $6.96
- Resistance Level
- XBP $0.63
- MRSN $7.68
- Average True Range (ATR)
- XBP 0.08
- MRSN 0.58
- MACD
- XBP 0.00
- MRSN 0.19
- Stochastic Oscillator
- XBP 55.81
- MRSN 85.14
About XBP XBP Europe Holdings Inc.
XBP Europe Holdings Inc is a pan-European integrator of bills, payments, and related solutions and services seeking to enable digital transformation. It provides business process management solutions with proprietary software suites and deep domain expertise, serving as a technology and operations partner for its clients' strategic journeys and streamlining their complex, disconnected payment processes. It has two segments Bills and Payments focusing on optimizing how bills and payments are processed by businesses of all sizes and industries and Technology, focuses on sales of recurring and perpetual software licenses and related maintenance, hardware solutions, and related maintenance and professional services. It generates the majority of its revenue from the Bills and Payments segment.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.